期刊文献+

Peperomia pellucida(L.) Kunth and eye diseases: A review on phytochemistry, pharmacology and toxicology

原文传递
导出
摘要 Peperomia pellucida(L.) Kunth is a medicinal plant used to manage inflammatory illnesses such as conjunctivitis, and gastrointestinal and respiratory tract disorders in tropical and subtropical regions.However, little is known about its pharmacological mechanism of action against eye diseases. This review aims to critically discuss the phytochemistry, pharmacology and toxicology of P. pellucida as well as its roles in the treatment of cataract, glaucoma and diabetic retinopathy. Recent developments in the uses of P. pellucida for healthcare and nutraceutical products by the pharmaceutical industry are also covered in this review. For this review, a literature search was performed with PubMed, ScienceDirect, SciFinder Scholar and Scopus databases, using relevant keywords. Among the various phytochemicals identified from P. pellucida, β-caryophyllene, carotol, dillapiole, ellagic acid, pellucidin A, phytol and vitexin exhibit strong pharmacological activities within the mitogen-activated protein kinase and nuclear factor-κB signalling pathways in inflammatory eye diseases. The antihypertensive, anti-inflammatory, antioxidant,antihyperglycemic and anti-angiogenic activities displayed by P. pellucida extracts in many in vitro,in vivo and clinical studies suggest its potential role in the management of inflammatory eye diseases.P. pellucida extract was non-toxic against normal cell lines but displayed mild toxicity in animal models.The growing public interest in P. pellucida has inspired the nutraceutical and pharmaceutical industries to process the plant into health products. Although the potential pharmacological mechanisms against eye diseases have been summarized, further studies of the interactions among constituent phytochemicals from P. pellucida within various signalling pathways shall support the use of the plant as an alternative therapeutic source.
出处 《Journal of Integrative Medicine》 SCIE CAS CSCD 2022年第4期292-304,共13页 结合医学学报(英文版)
基金 supported by the Ministry of Higher Education Malaysia (FRGS/1/2019/SKK06/UNIM/02/1)。
  • 相关文献

参考文献3

二级参考文献72

  • 1Kultigin Turkmen,Ali Karagoz,Adem Kucuk.Sirtuins as novel players in the pathogenesis of diabetes mellitus[J].World Journal of Diabetes,2014,5(6):894-900. 被引量:4
  • 2Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalenceof diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14[PMID: 19896746 DOI: 10.1016/j.diabres.2009.10.007].
  • 3World Health Organization. Diabetes Action Now: An Initiativeof the World Health Organization and the International DiabetesFederation. Switzerland: World Health Organization, 2004.
  • 4Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E.Screening and prevention of diabetic blindness. Acta OphthalmolScand 2000; 78: 374-385 [PMID: 10990036 DOI: 10.1034/j.1600-0420.2000.078004374.x].
  • 5Prokofyeva E, Zrenner E. Epidemiology of major eye diseasesleading to blindness in Europe: a literature review. Ophthalmic Res2012; 47: 171-188 [PMID: 22123077 DOI: 10.1159/000329603].
  • 6Hammes HP. Optimal treatment of diabetic retinopathy. Ther AdvEndocrinol Metab 2013; 4: 61-71 [PMID: 23626903 DOI: 10.1177/2042018813477886].
  • 7Deutsche DG. Nationale VersorgungsLeitlinie Typ-2-DiabetesPr-vention und Therapie von Netzhautkomplikationen. Berlin:Bundes-rztekammer (B-K), 2010: 1-42.
  • 8Giani G, Janka HU, Hauner H, Standl E, Schiel R, Neu, A.Epidemiologie und Verlauf des Diabetes mellitus in Deutschland.Evidenzbasierte Leitlinie DDG-Aktualisierung 2004; 5: 1-12.
  • 9Nentwich MM, Ulbig M. Diabetische Retinopathie. DerDiabetologe 2010; 6: 491-502 [DOI: 10.1007/s11428-010-0605-8].
  • 10Kramer CK, Retnakaran R. Concordance of retinopathy andnephropathy over time in Type 1 diabetes: an analysis of data fromthe Diabetes Control and Complications Trial. Diabet Med 2013;30: 1333-1341 [PMID: 23909911 DOI: 10.1111/dme.12296].

共引文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部